Expired
Lead Plaintiff Deadline
Apr 3, 2023
Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that:
(a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants’ claims regarding ADG20’s efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.
In order to be eligible to join the IVVD class action lawsuit, you must have incurred a loss on shares of Invivyd purchased during the class period listed above.
If you suffered a loss in Invivyd during the relevant time frame or pursuant to the relevant offering(s), you have until April 3, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a IVVD class action lawsuit has been filed on behalf of investors who purchased Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) common stock between November 29, 2021 and December 14, 2021. For more on the IVVD Lawsuit please contact us today.
According to the Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants’ claims regarding ADG20’s efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.
If you suffered a loss in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. you have until April 3, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
TOP
